Methylergonovine Shortage: What Providers and Prescribers Need to Know in 2026

If your patients have reported difficulty filling Methylergonovine prescriptions, you're seeing a pattern that has been building for several years. This briefing provides a comprehensive update on the current supply landscape for Methylergonovine maleate (formerly brand Methergine), what it means for clinical practice, and what tools are available to help your patients access this medication — or appropriate alternatives.

Supply Trajectory: How We Got Here

Brand discontinuation: Novartis permanently discontinued brand-name Methergine, removing the original product from the market entirely.

Generic entry (2021): Lupin Pharma launched generic Methylergonovine maleate tablets (0.2 mg), providing a new supply source.

Injectable shortages: The injectable form (0.2 mg/mL) has appeared on FDA and ASHP drug shortage lists multiple times, with manufacturing and supply chain issues contributing to intermittent availability.

March 2026 — FDA ruling: FDA determined injectable Methergine (0.2 mg/mL) was not withdrawn for safety or effectiveness reasons, enabling generic ANDA submissions. This opens the path for additional injectable manufacturers to enter the market.

Current state (2026): Oral tablets available through limited manufacturers but retail distribution is inconsistent. Injectable form continues to face periodic supply constraints. Check the ASHP Drug Shortages Resource Center for real-time status.

Current Supply Forms and Availability

Oral tablets (0.2 mg): Manufactured by Lupin Pharma and potentially other generic suppliers. Available through major pharmaceutical wholesalers, but not consistently stocked at retail pharmacies due to low demand volume per location.

Injectable (0.2 mg/mL): Periodic supply constraints continue. Check the ASHP Drug Shortage database for current status. Hospital pharmacy should maintain close communication with their distributor.

Brand-name Methergine: Permanently discontinued. Not expected to return to market.

Clinical Implications for Prescribers

The inconsistent availability of Methylergonovine has practical implications for obstetric prescribing. Patients discharged with a Methylergonovine prescription may find their local pharmacy doesn't stock it. For a new mother managing postpartum recovery and a newborn, the burden of pharmacy shopping is significant — and potentially dangerous if hemorrhage risk is present.

Clinical considerations include:

Verify local pharmacy availability before discharge whenever possible, or prescribe an alternative proactively if supply is known to be limited.

Have a documented alternative plan (e.g., misoprostol) ready if the patient cannot fill the Methylergonovine prescription.

Cost presents an additional access barrier: retail cash price can be up to $375 for 6 tablets. Discount coupon price runs $28–$35 through GoodRx, SingleCare, and similar platforms. Counsel patients to use coupons before paying retail price.

Evidence-Based Alternatives When Methylergonovine Is Unavailable

When Methylergonovine is unavailable, the following evidence-based alternatives should be considered:

Oxytocin (Pitocin): First-line uterotonic per ACOG guidelines for PPH prevention and treatment. IV/IM only. Safe in hypertensive patients.

Misoprostol (Cytotec): Oral/sublingual/rectal prostaglandin E1 analog. Widely available, often under $5 with a coupon, suitable for at-home use. Key alternative when patients need an oral option. Safe in hypertension.

Carboprost (Hemabate): IM prostaglandin F2-alpha. Hospital use only. Contraindicated in asthma. Effective for refractory uterine atony.

Tranexamic acid: IV antifibrinolytic adjunct. Per WHO guidelines, administer within 3 hours of delivery for maximum benefit.

Key Pharmacology Reminder: Contraindications

When Methylergonovine is available and appropriate, ensure prescriptions avoid documented contraindications:

Hypertension, preeclampsia, or eclampsia — vasoconstriction risk

Strong CYP3A4 inhibitors (macrolide antibiotics, HIV protease inhibitors, azole antifungals) — risk of acute ergot toxicity

Coronary artery disease or significant CAD risk factors

Peripheral vascular disease

Pregnancy (before delivery)

Tools to Help Your Patients Find Methylergonovine

Consider directing patients to medfinder.com/providers. medfinder calls pharmacies on behalf of patients to find which ones have a given medication in stock — reducing the burden on the patient and on your staff. This is particularly valuable for a medication like Methylergonovine where availability varies significantly by pharmacy.

Additional resources for monitoring supply:

ASHP Drug Shortages Resource Center: ashp.org/drug-shortages

FDA Drug Shortage Database: accessdata.fda.gov/scripts/drugshortages

Summary for Practice

Brand-name Methergine is permanently gone — generic Methylergonovine maleate is the only option

Oral tablet supply is inconsistent at retail pharmacies; injectable supply faces periodic shortages

Have an alternative plan — misoprostol is widely available and often costs under $5

Retail cash price up to $375; counsel patients to use GoodRx or SingleCare coupons ($32–$35)

Direct patients to medfinder to find which pharmacies near them stock Methylergonovine